8-K: Xtant Medical Achieves Profitability, Strong Cash Flow in 2025

Xtant Medical reported a transformational 2025, achieving full-year profitability and positive operating cash flow, driven by revenue growth and strategic divestitures.

Summary

• Full-year 2025 revenue totaled $133.9 million, an increase of 14% over full-year 2024.
• Achieved positive net income of $5.0 million, or $0.03 per diluted share, for full-year 2025, compared to a net loss of $16.5 million in 2024.
• Reported non-GAAP adjusted EBITDA of $16.3 million for full-year 2025, a significant improvement from an adjusted EBITDA loss of $2.3 million in 2024.
• Generated $12.5 million in net cash from operations for full-year 2025, reversing a net cash used in operations of $11.9 million in 2024.
• Fourth quarter 2025 revenue was $32.4 million, up approximately 3% compared to the prior year quarter, despite an estimated $2.0 million reduction due to an earlier-than-anticipated divestiture closing.
• Fourth quarter 2025 net income was $0.1 million, compared to a net loss of $3.2 million in the prior year quarter.
• Completed the sale of non-core Coflex and CoFix assets and international hardware businesses to Companion Spine for a total sale price of $21.4 million in cash.
• Launched two new products: nanOss Strata, a next-generation synthetic bone graft, and CollagenX, a bovine collagen particulate product for surgical wound closure.
• Total cash was $17.3 million as of December 31, 2025, with an additional $10.5 million received in February 2026 related to the Companion Spine divestiture.
• Reduced the term loan balance to $11.2 million.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report, highlighting a successful strategic transformation leading to profitability, positive cash flow, and a strengthened balance sheet, despite a projected revenue decrease in 2026 due to divestitures.

Positives

• Full-year 2025 revenue increased 14% to $133.9 million.
• Achieved positive net income of $5.0 million for full-year 2025, a significant improvement from a $16.5 million loss in 2024.
• Reported positive non-GAAP adjusted EBITDA of $16.3 million for full-year 2025, reversing a $2.3 million loss in 2024.
• Generated $12.5 million in net cash from operations for full-year 2025, compared to $11.9 million used in 2024.
• Gross margin improved to 62.9% for full-year 2025 (from 58.2% in 2024) and 54.9% for Q4 2025 (from 50.8% in Q4 2024).
• Successfully divested non-core Coflex and CoFix assets and international hardware businesses for $21.4 million in cash.
• Launched two new innovative products: nanOss Strata (synthetic bone graft) and CollagenX (bovine collagen particulate).
• Strengthened cash position to $17.3 million as of December 31, 2025, with an additional $10.5 million received in February 2026.
• Reduced term loan balance to $11.2 million.
• Expects to be free cash flow positive in 2026 and does not anticipate needing to raise additional outside capital.
• Began opportunistically adding to the field sales force in Q4 2025 and into Q1 2026.

Negatives

• Fourth quarter 2025 revenue was reduced by an estimated $2.0 million due to the earlier-than-anticipated closing of the Companion Spine transaction.
• Increased charges for excess and obsolete inventory, including a $1.3 million charge related to the Cortera Fixation System launch.
• Anticipates full-year 2026 revenue guidance of $95 million to $99 million, a decrease from 2025, due to the divestiture and cessation of certain license revenues.

Risks

• Future operating results, financial performance, and need for additional capital.
• The success of the expanded field sales force to improve reach and leverage the contract portfolio and independent agent network.
• Ability to become operationally self-sustaining and less reliant on third-party manufacturers and suppliers.
• Risks associated with acquisitions and dispositions.
• Ability to successfully implement future growth initiatives and risks associated therewith.
• Possible future impairment charges to long-lived assets and goodwill and write-downs of excess and obsolete inventory.
• Ability to continue to innovate, develop, and introduce new products and the success of those products.
• Ability to remain competitive.
• Ability to engage and retain new and existing independent distributors and agents and qualified sales and other personnel, and dependence on key independent agents for a significant portion of revenue.
• The effect of inflation, elevated interest rates, other recessionary factors, and supply chain disruptions.
• The effect of product sales mix changes on financial results.
• The effect of government and third-party coverage and reimbursement for products.
• Ability to obtain and maintain regulatory approvals and comply with government regulations.
• The effect of product liability claims and other litigation to which the company may be subject.
• The effect of product recalls and defects.
• Ability to license intellectual property on commercially reasonable terms and to maintain any such licenses, and ability to obtain and protect intellectual property and proprietary rights and operate without infringing the rights of others.
• Ability to service debt, comply with debt covenants, and access additional indebtedness or financing on favorable terms or at all, if and when needed.

Future Outlook

Xtant Medical anticipates full-year 2026 revenue to be in the range of $95 million to $99 million. This outlook reflects anticipated organic growth in its core higher-margin biologics business, offset by the impact of the December 2025 divestiture and cessation of certain license revenues. The company expects to be free cash flow positive in 2026 and does not foresee a need to raise additional outside capital for operations.

Management Comments

• Our fourth quarter 2025 caps a truly transformational year for Xtant, during which we meaningfully sharpened our focus on our core biologics business while driving the new product innovation for which we are known.
• Along the way, in 2025 we achieved profitability and cash flow generation, reflecting robust topline growth, targeted R&D investments, and prudent expense management.
• With this foundation in place, we began to opportunistically add to our field sales force in the fourth quarter 2025 and into the first quarter of 2026 to improve our reach and leverage our outstanding contract portfolio and independent agent network.
• Given our significantly strengthened financial position, we do not see any need to raise additional outside capital to run our operations and we expect to be free cash flow positive in 2026.
• Moreover, this year we plan to lean into our strengths in biologics and invest in our commercial team to focus on profitably growing our core biologics business.

Industry Context

StockSavvy.ai notes that Xtant Medical's strategic divestiture of non-core assets and focus on higher-margin biologics aligns with a broader industry trend among medical technology companies to streamline operations and concentrate on specialized, high-growth segments. The launch of new synthetic bone graft and collagen products positions Xtant to compete in the evolving orthobiologics and wound care markets, where innovation and product differentiation are key drivers of market share.

Stakeholder Impact

• Shareholders: Potential positive impact due to improved financial performance, achievement of profitability, positive cash flow generation, strengthened balance sheet, and management's confidence in not needing to raise additional capital.
• Employees: Potential positive impact from the opportunistic expansion of the field sales force.
• Customers: Benefit from the commercial launch of new innovative products like nanOss Strata and CollagenX, offering advanced surgical solutions.

Next Steps

• Continue to opportunistically add to the field sales force in Q1 2026 to improve reach and leverage the contract portfolio and independent agent network.
• Focus on profitably growing the core biologics business in 2026.
• Invest in the commercial team in 2026.
• Host a webcast and conference call on March 31, 2026, to discuss the fourth quarter and full-year 2025 financial and operating results.
• File the Annual Report on Form 10-K for the year ended December 31, 2025, with the SEC on March 30, 2026.

Key Dates

Recommendation

The company has demonstrated a significant turnaround, achieving full-year profitability and positive operating cash flow after a strategic divestiture. The strengthened balance sheet, coupled with management's confidence in not requiring additional capital and projecting free cash flow positive status in 2026, indicates robust financial health and a clear strategic direction towards higher-margin biologics. The launch of new products further supports future growth, making this a compelling investment opportunity.

Keywords

Xtant Medical, XTNT, Financial Results, Q4 2025, Full-Year 2025, Revenue, Net Income, Adjusted EBITDA, Orthobiologics, Spinal Solutions, Medical Technology, Divestiture, Product Launch, nanOss Strata, CollagenX, Cash Flow, Profitability, SEC Filing, 8-K